Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 9/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.31 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838324 | 0.85 | CALCA (0.47) | CALCACYP2C9KCNH2 | |
| SCHEMBL5580069 | 0.85 | CYP2C9 (0.45) | CALCACYP2C9KCNH2ENPP2ATXN2 | |
| SCHEMBL5538235 | 0.85 | CYP2C9 (0.36) | CALCACYP2C9KCNH2ENPP2ATXN2 | |
| SCHEMBL3836134 | 0.85 | CALCA (0.46) | CALCACYP2C9KCNH2 | |
| SCHEMBL3842593 | 0.83 | CALCA (0.45) | CALCACYP2C9KCNH2 | |
| SCHEMBL12777245 | 0.83 | KCNH2 (0.36) | CALCACYP2C9KCNH2HDAC3HDAC1 | |
| SCHEMBL12777247 | 0.83 | ALOX15 (0.37) | CALCACYP2C9KCNH2 | |
| SCHEMBL2080375 | 0.82 | CYP2C9 (0.42) | CALCACYP2C9KCNH2ENPP2ATXN2 | |
| SCHEMBL2079357 | 0.81 | CDK9 (0.34) | CYP2C9ENPP2ATXN2HDAC3HDAC1 | |
| SCHEMBL2082156 | 0.81 | OPRD1 (0.34) | CALCACYP2C9ENPP2ATXN2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007143446-A1 | SPIRO-CONDENSED HETEROTRICYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-13 | — | — | WO | claimed |
| US-20070281917-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-06 | — | — | US | claimed |
| US-7897593-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20070281917-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281917-A1 | HIV Integrase Inhibitors | TYMP, POLN, IMPDH1 | CALCA 3114/4885CYP2C9 704/4885KCNH2 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.